Novo Nordisk to Cut Ozempic, Wegovy Prices Up to 50% in 2027

Novo Nordisk announced plans to slash list prices of Ozempic and Wegovy by up to 50% in the United States starting in 2027, as the Danish pharmaceutical company prepares for intensifying competition from generic alternatives.

Significant Price Reductions Planned

The company confirmed that Ozempic prices will drop by 35%, while Wegovy will see a 50% price reduction. These cuts represent some of the most substantial price decreases announced by a major pharmaceutical manufacturer for GLP-1 receptor agonist medications.

The announcement comes as Novo Nordisk faces mounting pressure from cheaper alternatives entering the market. In Canada, semaglutide patent protection expired in January 2026, opening the door for generic competitors to enter the market with significantly lower-priced versions of the active ingredient found in both medications.

Generic Competition Driving Market Changes

Health Canada is currently reviewing nine applications for generic semaglutide products, with approvals expected by mid-2026. Companies including Sandoz, Teva, and other major generic manufacturers have submitted applications to produce biosimilar versions of the medication.

Industry experts anticipate generic versions could cost 60-70% less than current brand-name prices. Current Canadian retail prices for a four-week supply range from $400 to $570 CAD depending on dosage strength and pharmacy location.

Canadian Market Implications

While Novo Nordisk's announced price cuts apply specifically to the U.S. market, the move signals broader competitive pressures that could influence Canadian pricing strategies. The company has not announced similar price reductions for the Canadian market at this time.

Canadian patients currently pay between $200-$600 monthly for GLP-1 medications depending on insurance coverage and pharmacy choice. Many rely on employer drug plans or provincial coverage programs to offset costs.

The generic semaglutide tracker shows increasing activity from multiple pharmaceutical companies preparing market entry strategies for Canada.

Regulatory Status and Market Access

Both Ozempic (0.25mg, 0.5mg, 1mg, 2mg strengths) and Wegovy (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg strengths) remain fully approved by Health Canada for their respective indications. The medications are available at major pharmacy chains including Shoppers Drug Mart, Costco, Walmart, and Rexall across all Canadian provinces.

Patients seeking coverage information can use the insurance coverage checker to determine eligibility under various provincial and private insurance plans.

Industry Response to Price Competition

The announcement reflects broader industry trends as pharmaceutical companies adjust pricing strategies in anticipation of generic competition. Eli Lilly recently reduced Canadian prices for Mounjaro by 20% or more, setting four-week supplies at $300 CAD for lower dosage strengths.

These price adjustments come as approximately three million Canadians currently use GLP-1 medications according to recent survey data, representing a significant market for both brand-name and generic manufacturers.

Looking Ahead

The 2027 price reduction timeline coincides with expected broader generic availability in multiple markets. Canadian patients may benefit from both direct price competition and indirect pricing pressures as manufacturers compete for market share.

For current pricing information and pharmacy comparisons, patients can check the FAQ section for guidance on accessing these medications through various coverage options.

This article is for informational purposes only and does not constitute medical advice.